Showing results (51-60 of 104) with videos related to
Sort By:
Pageof 11
Alimentary Pharmacology & Therapeutics|June 1, 1987
Review: post-marketing surveillance of the safety of cimetidine--the problems of data interpretationD G Jones, M J Langman, D H Lawson, et al.American Journal of Ophthalmology|June 1, 2001
Retinopathy associated with high-dose interferon alfa-2b therapyC Hejny, P Sternberg, D H Lawson, et al.British Medical Journal (Clinical Research Ed.)|April 9, 1983
Hyperkalaemia in patients in hospitalB Paice, J M Gray, D McBride, et al.Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|January 1, 1984
Urinary cancer-related protein EDC1 and serum inter-alpha trypsin inhibitor in breast cancerR K Chawla, F W Miller, D H Lawson, et al.The Quarterly Journal of Medicine|July 1, 1976
Potassium supplements in patients receiving long-term diuretics for oedemaD H Lawson, K Boddy, J M Gray, et al.The Journal of Investigative Dermatology|March 1, 1986
Growth factor and cytogenetic abnormalities in cultured nevi and malignant melanomasA Richmond, R Fine, D Murray, et al.Journal of Clinical Pharmacology|November 1, 1986
Whole-body composition in patients with angina pectoris receiving long-term treatment with the nonselective beta-receptor blocking drug nadololJ M Gray, B W East, I Robertson, et al.British Medical Journal (Clinical Research Ed.)|November 6, 1982
Cimetidine and gastric cancer: preliminary report from post-marketing surveillance studyD G Colin-Jones, M J Langman, D H Lawson, et al.British Medical Journal (Clinical Research Ed.)|May 28, 1983
Postmarketing surveillance of the safety of cimetidine: 12 month mortality reportD G Colin-Jones, M J Langman, D H Lawson, et al.British Medical Journal (Clinical Research Ed.)|October 19, 1985
Postmarketing surveillance of the safety of cimetidine: mortality during second, third, and fourth years of follow upD G Colin-Jones, M J Langman, D H Lawson, et al.Pageof 11